ST
ITCI

Stifel Trust’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Stifel Trust’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$165K Buy
12,000
+1,000
+9% +$15K 0.03% 193
2014
Q2 		$186K Buy
11,000
+8,500
+340% +$140K 0.03% 184
2014
Q1 		$46K Buy
+2,500
New +$45.1K 0.01% 277

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Stifel Trust's ITCI Position: Q3 2014 in Review

Stifel Trust increased its Intra-Cellular Therapies Inc. (ITCI) stake by 9.1% in Q3 2014, buying an estimated $15K and bringing the position to 12,000 shares worth $165K. The position accounts for 0.03% of the portfolio, ranked #193.

Stifel Trust first reported a position in ITCI in Q1 2014 and has held it in 3 quarters since. The position peaked at $186K in Q2 2014. 49 funds tracked by Wall St. Rank hold ITCI as of Q3 2014.

  • Stifel Trust held 12,000 shares of Intra-Cellular Therapies Inc. worth $165K as of Q3 2014.
  • Stifel Trust bought 1,000 Intra-Cellular Therapies Inc. shares in Q3 2014, an estimated $15K.
  • Intra-Cellular Therapies Inc. made up 0.03% of Stifel Trust's portfolio in Q3 2014, its #193 holding.
  • Stifel Trust first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and has held it in 3 quarters since.
  • Stifel Trust's Intra-Cellular Therapies Inc. position peaked at $186K in Q2 2014.
  • 49 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2014.

Based on Stifel Trust's 13F filing for Q3 2014, filed 14 Nov 2014.